Vertex Pharmaceuticals Rating Increased to Buy at Brean Murray Carret & Co. (VRTX)
A number of other firms have also recently commented on VRTX. Analysts at Brean Murray upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at JPMorgan Chase (NYSE: JPM) reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday. Finally, analysts at JMP Securities upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Monday.
Shares of Vertex Pharmaceuticals traded up 2.72% during mid-day trading on Monday, hitting $59.70. Vertex Pharmaceuticals has a 52 week low of $26.50 and a 52 week high of $58.87. The company has a market cap of $12.589 billion and a P/E ratio of 41.34.
Vertex Pharmaceuticals last announced its earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.